NCT05823311View on ClinicalTrials.gov

Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Advanced Cholangiocarcinoma
Interventions
DRUG

Lenvatinib, tislelizumab, gemcitabine and cisplatin

Intravenous injection: gemcitabine and cisplatin (CG) + tislelizumab； Oral administration: lenvatinib.

DRUG

Gemcitabine and cisplatin

Intravenous injection: gemcitabine and cisplatin (CG) + placebo； Oral administration: placebo.

Trial Locations (1)

310009

RECRUITING

The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

collaborator

The Affiliated Tumor Hospital of Xinjiang Medical University

UNKNOWN

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER